Tgfbr1 Haploinsufficiency Inhibits the Development of Murine Mutant Kras-Induced Pancreatic Precancer

被引:23
作者
Adrian, Kevin
Strouch, Matthew J.
Zeng, Qinghua [3 ,4 ]
Barron, Morgan R.
Cheon, Eric C. [5 ]
Honasoge, Akilesh
Xu, Yanfei [2 ]
Phukan, Sharbani [2 ]
Sadim, Maureen [2 ]
Bentrem, David J.
Pasche, Boris [3 ,4 ]
Grippo, Paul J. [1 ]
机构
[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Dept Surg, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Dept Med, Div Hematol Oncol,Canc Genet Program, Chicago, IL 60611 USA
[3] Univ Alabama, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA
[4] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA
[5] Univ Illinois, Dept Surg, Mt Sinai Hosp, Chicago, IL 60680 USA
关键词
DUCTAL ADENOCARCINOMA; COLORECTAL-CANCER; TUMOR SUPPRESSION; BETA RECEPTORS; EXPRESSION; SMAD4; PROGRESSION; ACTIVATION; PROGNOSIS; NEOPLASIA;
D O I
10.1158/0008-5472.CAN-09-1705
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
To dissect the role of constitutively altered Tgfbr1 signaling in pancreatic cancer development, we crossed Elastase-Kras(G12D) (EL-Kras) mice with Tgfbr1 haploinsufficient mice to generate EL-Kras/Tgfbr1(+/-) mice. Mice were euthanized at 6 to 9 months to compare the incidence, frequency, and size of precancerous lesions in the pancreas. Only 50% of all EL-Kras/Tgfbr1(+/-) mice developed preinvasive lesions compared with 100% of EL-Kras (wild-type Tgfbr1) mice. The frequency of precancerous lesions was 4-fold lower in haploinsufficient than in control mice. Paradoxically, the precancerous lesions of EL-Kras/Tgfbr1(+/-) mice were considerably larger than those in EL-Kras mice. Yet, the mitotic index of precancerous cells and the observable levels of fibrosis, lipoatrophy, and lymphocytic infiltration were reduced in EL-Kras/Tgfbr1(+/-) mice. We conclude that Tgfbr1 signaling promotes the development of precancerous lesions in mice. These findings suggest that individuals with constitutively decreased TGFBR1 expression may have a decreased risk of pancreatic cancer. [Cancer Res 2009;69(24):9169-74]
引用
收藏
页码:9169 / 9174
页数:6
相关论文
共 24 条
[1]  
Baldwin RL, 1996, INT J CANCER, V67, P283, DOI 10.1002/(SICI)1097-0215(19960717)67:2<283::AID-IJC21>3.0.CO
[2]  
2-B
[3]   Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer [J].
Bardeesy, Nabeel ;
Cheng, Kuang-hung ;
Berger, Justin H. ;
Chu, Gerald C. ;
Pahler, Jessica ;
Olson, Peter ;
Hezel, Aram F. ;
Horner, James ;
Lauwers, Gregory Y. ;
Hanahan, Douglas ;
DePinho, Ronald A. .
GENES & DEVELOPMENT, 2006, 20 (22) :3130-3146
[4]   SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer [J].
Blackford, Amanda ;
Serrano, Oscar K. ;
Wolfgang, Christopher L. ;
Parmigiani, Giovanni ;
Jones, Sian ;
Zhang, Xiaosong ;
Parsons, D. Williams ;
Lin, Jimmy Cheng-Ho ;
Leary, Rebecca J. ;
Eshleman, James R. ;
Goggins, Michael ;
Jaffee, Elizabeth M. ;
Iacobuzio-Donahue, Christine A. ;
Maitra, Anirban ;
Cameron, John L. ;
Olino, Kelly ;
Schulick, Richard ;
Winter, Jordan ;
Herman, Joseph M. ;
Laheru, Daniel ;
Klein, Alison P. ;
Vogelstein, Bert ;
Kinzler, Kenneth W. ;
Velculescu, Victor E. ;
Hruban, Ralph H. .
CLINICAL CANCER RESEARCH, 2009, 15 (14) :4674-4679
[5]   TGF-β signaling in tumor suppression and cancer progression [J].
Derynck, R ;
Akhurst, RJ ;
Balmain, A .
NATURE GENETICS, 2001, 29 (02) :117-129
[6]   Transforming growth factors beta 1, beta 2, and beta 3 and their receptors are differentially regulated during normal and impaired wound healing [J].
Frank, S ;
Madlener, M ;
Werner, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (17) :10188-10193
[7]   ENHANCED EXPRESSION OF TRANSFORMING GROWTH-FACTOR-BETA ISOFORMS IN PANCREATIC-CANCER CORRELATES WITH DECREASED SURVIVAL [J].
FRIESS, H ;
YAMANAKA, Y ;
BUCHLER, M ;
EBERT, M ;
BEGER, HG ;
GOLD, LI ;
KORC, M .
GASTROENTEROLOGY, 1993, 105 (06) :1846-1856
[8]  
Goggins M, 1998, CANCER RES, V58, P5329
[9]  
Grippo P. J., 2004, Pancreas, V29, P335, DOI 10.1097/00006676-200411000-00047
[10]  
Grippo PJ, 2003, CANCER RES, V63, P2016